Purchase this article with an account.
S. J. Kang, C. Durairaj, U. B. Kompella, J. M. O'Brien, K. Liu, H. E. Grossniklaus; Subconjunctival Nanoparticle Carboplatin in the Treatment of Transgenic Murine Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2017. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of subconjunctival nanoparticle carboplatin in the treatment of transgenic murine retinoblastoma.
Dendrimeric nanoparticles loaded with carboplatin were prepared. LHβ-Tag mice were randomly assigned into 3 groups, and treated at 10 weeks of age. Each mouse received a single subconjunctival injection in one eye, and the opposite eye was left untreated as a control. Group 1 (nanoparticle group, 10 mice) received 37.5 mg/ml nanoparticle carboplatin (0.66 mg measured total dose). Group 2 (conventional group, 10 mice) received same concentration of conventional carboplatin, and group 3 (PBS group, 5 mice) received PBS. Mice were killed on day 22 after treatment. Eyes were serially sectioned, and retinal tumor burden was quantified by histopathologic analysis.
Mean tumor burden in the nanoparticle group was significantly smaller compared to the untreated eyes in the same mice (P < 0.02), conventional carboplatin-treated group (P < 0.02), and PBS treated group (P < 0.001). A single subconjunctival injection of conventional carboplatin did not show significant decrease in tumor burden compared to the PBS treated group (P = 0.82). No histologic evidence of toxicity was observed in any of the groups.
A single injection of subconjunctival nanoparticle carboplatin was effective in the treatment of transgenic murine retinoblastoma with no associated toxicity.
This PDF is available to Subscribers Only